Case Study: Application of Captisol® Technology to Enable the Formulation of Remdesivir in Treating COVID-19

[Article Title]

Captisol is a proprietary sulfobutylether-cyclodextrin process-specifi c composition that is a mixture of
regional and positional isomers consistently produced via a patented all-aqueous process originally
discovered at the University of Kansas. The motivation for Captisol’s discovery was to provide a
parenterally safe material broadly applicable across all drug classes for solubilizing and stabilizing
intractable drug candidates as opposed to historically used toxic cosolvents and surfactants.

Download the Document

    * denotes a required field

    Please fill out the information below. If you are already registered, and this information will be filled out for you.

  • Please enter your first and last name.

  • Please enter the name of the company or institution you work at.

  • Please enter your mailing address.

  • Please enter the e-mail address you would like to be contacted at.

  • Please enter the phone number you would like to be contacted at.

    • By submitting this form, you consent to American Pharmaceutical Review storing your email address and contact information and transmitting your contact information to the content sponsor. You may request to be removed at any time.